A
Anda M. Vlad
Researcher at University of Pittsburgh
Publications - 53
Citations - 1994
Anda M. Vlad is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Ovarian cancer & Immune system. The author has an hindex of 22, co-authored 41 publications receiving 1634 citations. Previous affiliations of Anda M. Vlad include Paul Scherrer Institute.
Papers
More filters
Book ChapterDOI
MUC1 immunobiology: from discovery to clinical applications.
Journal ArticleDOI
Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.
Swati Suryawanshi,Anda M. Vlad,Hui Min Lin,Gina M. Mantia-Smaldone,R. Laskey,MinJae Lee,Yan Lin,Nicole Donnellan,Marcia Klein-Patel,Ted Lee,Suketu Mansuria,Esther Elishaev,Raluca Budiu,Robert P. Edwards,Xin Huang +14 more
TL;DR: It is reported for the first time that distinct plasma miRNA expression patterns may serve as highly specific and sensitive diagnostic biomarkers to discriminate between healthy, endometriosis, and EAOC cases.
Journal ArticleDOI
The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells
TL;DR: This work has identified a new mechanism by which potentially immunogenic glycoprotein tumor Ags, such as MUC1, fail to stimulate strong immune responses, and shows that a 140-aa-long synthetic peptide is very efficiently processed by dendritic cells.
Journal ArticleDOI
Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.
Anda M. Vlad,Stefan Müller,Mare Cudic,Hans Paulsen,Laszlo Otvos,Franz-Georg Hanisch,Olivera J. Finn +6 more
TL;DR: It is shown that DCs endocytose MUC1 glycopeptides, transport them to acidic compartments, process them into smaller peptides, and present them on major histocompatability complex (MHC) class II molecules without removing the carbohydrates, suggesting that a much broader repertoire of T cells could be elicited against M UC1 and other glycoproteins than expected based only on their peptide sequences.
Journal ArticleDOI
Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
Shannon Grabosch,Mirna Bulatović,Feitianzhi Zeng,Feitianzhi Zeng,Tianzhou Ma,Tianzhou Ma,Lixin Zhang,Malcolm S. Ross,Joan Brozick,Yusi Fang,George C. Tseng,Eun Kim,Andrea Gambotto,Esther Elishaev,Robert P. Edwards,Anda M. Vlad +15 more
TL;DR: Cisplatin upregulates PD-L1 expression in vitro and in vivo, demonstrating a dual, paradoxical immune modulatory effect and supporting the rationale for combination with immune checkpoint blockade.